Stockscreener 앱 받기
990.33
0.72%
7.07
시간 외 거래:
985.00
-5.33
-0.54%
전일 마감가:
$983.26
열려 있는:
$975
하루 거래량:
2.62M
Relative Volume:
0.82
시가총액:
$884.36B
수익:
$65.18B
순이익/손실:
$20.64B
주가수익비율:
43.84
EPS:
22.5894
순현금흐름:
$5.96B
1주 성능:
-5.86%
1개월 성능:
-6.41%
6개월 성능:
+36.18%
1년 성능:
+8.50%
1일 변동 폭
$966.09
$991.22
1주일 범위
$965.60
$1,056.20
52주 변동 폭
$623.78
$1,133.95
일라이 릴리 Stock (LLY) Company Profile
명칭
Lilly Eli Co
전화
(317) 276-2000
주소
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, NVS, AZN
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
990.33 | 878.04B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
240.40 | 577.48B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
230.11 | 410.83B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
NVS
Novartis Ag Adr
|
160.12 | 307.23B | 54.72B | 14.02B | 15.32B | 7.1855 |
|
AZN
Astrazeneca Plc
|
194.22 | 306.31B | 58.80B | 10.24B | 8.98B | 3.2788 |
일라이 릴리 Stock (LLY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-25 | 개시 | RBC Capital Mkts | Outperform |
| 2026-02-20 | 개시 | Barclays | Overweight |
| 2026-01-07 | 재개 | UBS | Buy |
| 2025-12-16 | 업그레이드 | Daiwa Securities | Neutral → Buy |
| 2025-12-15 | 재확인 | BofA Securities | Buy |
| 2025-12-15 | 재확인 | Goldman | Buy |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-11-10 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-10-20 | 재확인 | BMO Capital Markets | Outperform |
| 2025-10-14 | 업그레이드 | Erste Group | Hold → Buy |
| 2025-09-17 | 다운그레이드 | Berenberg | Buy → Hold |
| 2025-08-27 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2025-08-18 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2025-08-07 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-06-05 | 다운그레이드 | Erste Group | Buy → Hold |
| 2025-04-28 | 다운그레이드 | HSBC Securities | Buy → Reduce |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-10 | 재개 | BofA Securities | Buy |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-10-17 | 개시 | Bernstein | Outperform |
| 2024-09-13 | 재개 | Citigroup | Buy |
| 2024-08-12 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2024-02-21 | 다운그레이드 | DZ Bank | Buy → Hold |
| 2024-02-16 | 재확인 | Morgan Stanley | Overweight |
| 2023-12-21 | 다운그레이드 | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-10-20 | 재개 | UBS | Buy |
| 2023-08-09 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-26 | 재확인 | Citigroup | Buy |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-05-24 | 재확인 | BofA Securities | Buy |
| 2023-05-24 | 재확인 | UBS | Buy |
| 2023-03-13 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | 개시 | Jefferies | Hold |
| 2023-02-15 | 다운그레이드 | Societe Generale | Hold → Sell |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-09-22 | 업그레이드 | UBS | Neutral → Buy |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2022-04-06 | 재개 | Morgan Stanley | Overweight |
| 2022-03-10 | 개시 | Daiwa Securities | Outperform |
| 2022-01-21 | 업그레이드 | DZ Bank | Hold → Buy |
| 2022-01-03 | 재확인 | Bernstein | Mkt Perform |
| 2021-12-17 | 개시 | Goldman | Neutral |
| 2021-12-16 | 재확인 | BMO Capital Markets | Outperform |
| 2021-12-16 | 재확인 | BofA Securities | Buy |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-10-11 | 업그레이드 | Berenberg | Hold → Buy |
| 2021-09-29 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-08-05 | 업그레이드 | DZ Bank | Hold → Buy |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-06-24 | 재확인 | Cantor Fitzgerald | Overweight |
| 2021-01-19 | 업그레이드 | Mizuho | Neutral → Buy |
| 2020-12-10 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | 재개 | Bernstein | Mkt Perform |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-09-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-04-21 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-04-09 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | 개시 | Mizuho | Neutral |
| 2019-12-18 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | 재개 | BofA/Merrill | Buy |
| 2019-05-28 | 개시 | Goldman | Buy |
| 2019-04-24 | 업그레이드 | Edward Jones | Hold → Buy |
| 2019-04-11 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-03-12 | 개시 | JP Morgan | Overweight |
| 2019-01-23 | 개시 | UBS | Buy |
| 2018-11-26 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2018-10-31 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | 개시 | Guggenheim | Buy |
| 2018-10-01 | 재확인 | SunTrust | Buy |
| 2018-09-26 | 재개 | JP Morgan | Overweight |
모두보기
일라이 릴리 주식(LLY)의 최신 뉴스
Down but Not Out: Is Novo Nordisk a Conditional Buy as Eli Lilly Leads the GLP‑1 Market? - The Motley Fool
Mounjaro weight loss trend: What Lilly’s hot drug really means for you - AD HOC NEWS
WHO Foundation announces collaboration with Lilly to strengthen health systems for obesity care | Corporate - EQS News
Chief technology officer spent whole career at Lilly - Indianapolis Business Journal
Morgan Stanley reiterates Overweight on Eli Lilly stock, $1,313 target By Investing.com - Investing.com India
Eli Lilly (LLY) Partners with GoodRx for Expanded Access to Zepb - GuruFocus
Eli Lilly: The One-Way Ride Can't Last Forever (Rating Downgrade) (NYSE:LLY) - Seeking Alpha
Talking Business with Don Cunningham: With Eli Lilly in the Valley, a life sciences flower blooms - The Morning Call
UBS Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,250 - 富途牛牛
Integrity Advisory Solutions LLC Makes New $1.07 Million Investment in Eli Lilly and Company $LLY - MarketBeat
Lilly plucks Flagship, bluebird vet for regenerative medicine unit; Novo's new China president - Endpoints News
Pitcairn Co. Sells 1,346 Shares of Eli Lilly and Company $LLY - MarketBeat
Roche's Obesity Drug Shows Promise But Trails GLP-1 Giants Novo Nordisk, Eli LillyRoche Holding (OTC:RHHBY) - Benzinga
‘Project Kennedy’: An inside look at the effort to bring Eli Lilly to Pa.’s Lehigh Valley | Opinion - lehighvalleylive
Upper Macungie approves tax breaks for Eli Lilly’s proposed manufacturing campus - WFMZ.com
Lilly targets employers in new bid to broaden access to obesity drugs - HR Dive
Eli Lilly and Company (NYSE:LLY) Trading Down 2.1%Here's Why - MarketBeat
Eli Lilly Just Launched a New Program to Make GLP‑1 Weight‑Loss Drugs Cheaper for Millions of Workers - inc.com
Teladoc Health joins Eli Lilly Employer Connect platform to expand workplace health options - Traders Union
Should You Forget Eli Lilly and Buy These Unstoppable Stocks Instead? - AOL.com
Morgan Stanley reiterates Eli Lilly stock rating on new obesity platform - Investing.com
Lilly Stock Down 5% in a Month: Should You Buy Now or Steer Clear? - Yahoo Finance UK
Eli Lilly (LLY) Launches Employer Connect for Obesity Drug Acces - GuruFocus
Eli Lilly and Company $LLY Shares Sold by Orion Porfolio Solutions LLC - MarketBeat
Eli Lilly Targets Employer Coverage Gap With New Obesity Drug Access Platform - Benzinga
This Under-the-Radar Stock Could Be the Next Big SplitAnd Early Investors Could Win Big - AOL.com
Lilly launches employer platform for obesity drug access - Investing.com
Eli Lilly and Co's first large-scale AI factory worldwide has been put into operation, equipped with over 1,000 GPUs. - 富途牛牛
Lilly launches employer-connect platform to broaden weight-loss drug access - Reuters
Eli Lilly launches program for employers to subsidize cost of obesity drug outside insurance - statnews.com
Eli Lilly launches program to help boost employer coverage of obesity drugs in U.S. - CNBC
Quantbot Technologies LP Cuts Stake in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly and Company $LLY Shares Acquired by Davidson Capital Management Inc. - MarketBeat
Crossmark Global Holdings Inc. Sells 1,008 Shares of Eli Lilly and Company $LLY - MarketBeat
Corient IA LLC Acquires 1,000 Shares of Eli Lilly and Company $LLY - MarketBeat
Cambria Investment Management L.P. Purchases 1,026 Shares of Eli Lilly and Company $LLY - MarketBeat
Lilly Employer Connect platform launches with over fifteen independent program administrators offering tailored obesity coverage options to expand access to patients - Eli Lilly and Company
Eli Lilly confirms oral GLP-1 weight-loss drug being evaluated by TGA - AFR
Eli Lilly’s Nvidia AI Deal And Pipeline Progress Versus Rich Valuation - simplywall.st
Eli Lilly and Company completed the acquisition of Ventyx Biosciences, Inc. from New Science Ventures, LLC, Affinity Asset Advisors, LLC, The Vanguard Group, Inc., and others. - marketscreener.com
Eli Lilly and booming weight-loss pharma industry now 20% of Irish goods exports - Irish Examiner
Ventyx Biosciences completes $1.2 billion acquisition by Eli Lilly, delists from Nasdaq - Investing.com India
Eli Lilly Unusual Options Activity For March 04 - Benzinga
Eli Lilly on track to launch oral obesity drug in second quarter, pending US approval - Reuters
Eli Lilly & Co (NYSE:LLY): A High-Growth Dividend Stock for Discerning Investors - ChartMill
Richard C. Young & CO. LTD. Makes New $13.88 Million Investment in Eli Lilly and Company $LLY - MarketBeat
Picton Mahoney Asset Management Lowers Holdings in Eli Lilly and Company $LLY - MarketBeat
GLP-1 Receptor Agonist Business Analysis Report 2026: Market to Reach $137.4 Billion by 2030 - GlobeNewswire Inc.
2 Top Growth Stocks to Buy in the First Half of 2026 - AOL.com
Does Lilly’s Broad Pipeline Wins in Obesity and Immunology Reshape the Bull Case for LLY? - simplywall.st
Bernstein Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,300 - 富途牛牛
일라이 릴리 (LLY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.32%
0.96%
자본화:
|
볼륨(24시간):